Catheter Locking Solution with Antimicrobial and Anticoagulant Properties
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Catheters face issues with microbial colonization and coagulation, leading to occlusions and infections, which existing anticoagulant solutions like heparin and citrate salts fail to address effectively, as they lack antimicrobial properties and can induce clotting or toxicity.
Innovation Solution
A catheter locking solution comprising a local anesthetic, such as dibucaine or tetracaine, combined with a viscosifying agent like polyethylene glycol, providing both antimicrobial and anticoagulant properties to prevent microbial colonization and coagulation within the catheter lumen.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If heparin lock solution is used to prevent catheter occlusion, then anticoagulation is improved, but antimicrobial protection deteriorates (heparin has no substantial antibacterial properties and may promote bacterial growth)
Solution Approach 1:
The patent combines heparin (anticoagulant) with an antimicrobial agent in a single lock solution formulation. This merging of two separate functional components into one solution simultaneously provides both anticoagulation and antimicrobial protection, resolving the contradiction where heparin alone failed to provide antimicrobial defense.
Solution Approach 2:
The lock solution is designed to perform multiple functions: anticoagulation (preventing clot formation) and antimicrobial protection (preventing bacterial colonization). This multi-functional solution replaces the single-function heparin lock, addressing both protection needs without requiring separate interventions.
2Reliability
If high concentration of heparin is infused to prevent occlusion, then anticoagulation is improved, but toxicity increases (excessive bleeding risk)
Solution Approach 1:
The patent modifies the concentration parameters of heparin within the lock solution, using optimized concentrations that provide sufficient anticoagulation to prevent occlusion while remaining below levels that cause excessive bleeding. The antimicrobial component allows for lower heparin concentrations compared to heparin-only solutions.
Solution Approach 2:
The lock solution uses a composite formulation combining heparin with antimicrobial agents. This composite approach allows the antimicrobial component to contribute to overall catheter protection, enabling reduced heparin dosing while maintaining both anticoagulation and infection prevention efficacy.
3Reliability
If sodium citrate is used as anticoagulant, then anticoagulation is improved, but antimicrobial activity deteriorates (no antimicrobial activity at low concentration)
Solution Approach 1:
The patent combines sodium citrate (anticoagulant) with an antimicrobial agent in a single lock solution. This combination allows the citrate to provide anticoagulation while the added antimicrobial component provides protection against bacterial colonization, resolving the limitation of citrate alone.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution enhances catheter patency, reduces the incidence of occlusions and infections, and prolongs catheter longevity by inhibiting microbial growth and coagulation, while maintaining safety by avoiding excessive bleeding or toxicity.
Implementation Method 1
certain compounds, such as dibucaine and tetracaine, have both antimicrobial and anticoagulant properties
Implementation Method 2
certain compounds, such as dibucaine and tetracaine, have both antimicrobial and anticoagulant properties
Implementation Method 3
The locking solution may include a viscosifying agent, such as polyethylene glycol
Data Source
AI summary
The present invention includes a catheter locking solution having both antimicrobial and anticoagulant properties including a local anesthetic and a viscosifying agent. The local anesthetic of the present invention may be an amino amide; an amino ester; an aminoacylanilide; an aminoalkyl benzoate; an amino carbonate; an N-phenylamidine compound; an N-aminoalkyl amid; an aminoketone, or combinations and mixtures thereof. In a particular embodiment of the present invention, the local anesthetic is tetracaine or dibucaine.